Log in to search using one of your social media accounts:

 

Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.

Processing and Reporting of Breast Specimens in the Neoadjuvant Setting. Surg Pathol Clin. 2018 Mar;11(1):213-230 Authors: Bossuyt V Abstract Standardization of quantification of residual disease in the breast and lymph nodes with routine pathologic macroscopic and microscopic evaluation leads to accurate and reproducible measures of response to neoadjuvant treatment. Multidisciplinary collaboration and correlation of clinical, imaging, gross and microscopic findings is essential. The processing approach to post-neoadjuvant breast cancer surgical specimens and the elements needed in the pathology report are the same regardless of breast cancer subtype or type of neoadjuvant treatment. The residual cancer burden incorporates response in the breast and in the lymph nodes into a score that can be combined with other emerging prognostic factors. PMID: 29413658 [PubMed - in process]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Surg Pathol Clin Source Type: research

Related Links:

Source: BMJ Comments - Category: General Medicine Source Type: forums
Condition:   Breast Cancer Triple Negative Intervention:   Drug: Goserelin Sponsor:   Kasr El Aini Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsNeoadjuvant versus adjuvant with standard anthracycline- and taxane-containing regimens results in similar disease-free survival and overall survival among patients with stage I and II triple-negative breast cancer regardless of BRCA status. Further studies are needed to evaluate whether similar results are observed with newer agents.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionAlthough the study was terminated owing to the altered liver function, it showed that there was a trend to greater shrinkage of tumor in the combination group for ER-positive, HER2-negative postmenopausal breast cancer.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionThe presence of microcalcifications on imaging and DCIS on initial CNB are associated with residual disease after neoadjuvant chemotherapy in TNBC. These variables can aid in identifying patients with TNBC suitable for inclusion in trials evaluating non‐surgical management after neoadjuvant chemotherapy.
Source: British Journal of Surgery - Category: Surgery Authors: Tags: Original article Source Type: research
CONCLUSION: The presence of microcalcifications on imaging and DCIS on initial CNB are associated with residual disease after neoadjuvant chemotherapy in TNBC. These variables can aid in identifying patients with TNBC suitable for inclusion in trials evaluating non-surgical management after neoadjuvant chemotherapy. PMID: 29465744 [PubMed - as supplied by publisher]
Source: The British Journal of Surgery - Category: Surgery Authors: Tags: Br J Surg Source Type: research
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent adverse reaction caused by chemotherapeutic agents, especially the taxanes. CIPN can persist from months to years after completion of chemotherapy, decreasing quality of life for cancer survivors. The aim of this study was to explore the incidence and risk factors of persistent CIPN among women with breast cancer receiving neoadjuvant chemotherapy.
Source: Journal of Psychosomatic Research - Category: Psychiatry & Psychology Authors: Source Type: research
CONCLUSIONS: we identified capecitabine as efficient chemotherapy in TNBC PDX models established from residual disease and resistant to anthracyclines, taxanes and platins. RB positivity and high expression of TYMP were significantly associated with capecitabine response. PMID: 29463559 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
This article reviews the impact of MR imaging in different settings on medical oncology decision-making in patients with breast cancer.
Source: Magnetic Resonance Imaging Clinics of North America - Category: Radiology Authors: Source Type: research
Contributors : Nicolai J Birkbak ; Andrea L RichardsonSeries Type : Expression profiling by arrayOrganism : Homo sapiensGene expression data from 21 triple negative breast cancer samples treated with cisplatin&bevacizumab in the neoadjuvant setting as part of a clinical trial.Gene expression data RMA normalized was used to find predictors of platinum sensitivity
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Neoadjuvant Therapy | Pathology